# Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

> **NCT01474109** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 289 (actual)

## Conditions studied

- Systemic Sclerosis
- Ulcers

## Interventions

- **DRUG:** macitentan 3mg
- **DRUG:** macitentan 10mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01474109
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2015-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01474109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01474109, "Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01474109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*